青光眼患者手术治疗的个体化
本文综述青光眼手术从传统滤过手术向个体化、精准治疗演变的趋势,讨论抗纤维化药物并发症、微创青光眼手术(MIGS)新装置涌现但随访短且缺乏优于传统方法证据的现状,强调早期诊断、个体化治疗和安全手术管理是青光眼治疗的核心。
要点
- 传统滤过手术联合抗纤维化药物提高成功率但增加并发症风险。
- MIGS新装置众多但随访短,缺乏优于传统手术的安全性和成本效果证据。
- 个体化手术需综合评估时机、危险因素、流出通路和瘢痕预防。
核心结论
- 青光眼手术需向个体化、精准化方向发展,结合个体数据选择治疗方式。
- 早期诊断、个体化治疗和安全手术管理应成为青光眼治疗的核心。
研究设计与样本
- 综述性文章,讨论青光眼个体化手术的当前知识与未来需求。
主要发现
- 传统滤过手术联合抗纤维化药物虽提高成功率,但与更多并发症相关,部分可能威胁视力。
- MIGS新装置针对流出通路新位点降低眼压,因操作相对简单且无明显严重副作用而日益普及。
- MIGS新技术仍处于早期经验阶段,随访短,缺乏优于传统方法的安全性和成本效果证据。
- 每年有多个新装置上市,同时也有装置退出市场。
临床怎么用
- 选择青光眼手术方式时需评估合适时机、个体危险因素、目标解剖和功能流出通路及瘢痕预防。
- 应用MIGS时需认识其随访短和证据有限的现状,不宜夸大其长期安全性和成本效果。
局限性
- MIGS新技术随访时间短,缺乏长期降眼压疗效和安全性的证据。
- 缺乏MIGS优于传统手术的安全性和成本效果证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Surgical treatments for glaucoma have relied for decades on traditional filtering surgery such as trabeculectomy and, in more challenging cases, tubes. Antifibrotics were introduced to improve surgical success in patients at increased risk of failure but have been shown to be linked to a greater incidence of complications, some being potentially vision-threatening. As our understanding of glaucoma and its early diagnosis have improved, a more individualised management has been suggested. Recently the term "precision medicine" has emerged as a new concept of an individualised approach to disease management incorporating a wide range of individual data in the choice of therapeutic modalities. For glaucoma surgery, this involves evaluation of the right timing, individual risk factors, targeting the correct anatomical and functional outflow pathways and appropriate prevention of scarring. As a consequence, there is an obvious need for better knowledge of anatomical and functional pathways and for more individualised surgical approaches with new, less invasive and safer techniques allowing for earlier intervention. With the recent advent of minimally invasive glaucoma surgery (MIGS) a large number of novel devices have been introduced targeting potential new sites of the outflow pathway for lowering intraocular pressure (IOP). Their popularity is growing in view of the relative surgical simplicity and apparent lack of serious side effects. However, these new surgical techniques are still in an era of early experiences, short follow-up and lack of evidence of their superiority in safety and cost-effectiveness over the traditional methods. Each year several new devices are introduced while others are withdrawn from the market. Glaucoma continues to be the primary cause of irreversible blindness worldwide and access to safe and efficacious treatment is a serious problem, particularly in the emerging world where the burden of glaucoma-related blindness is important and concerning. Early diagnosis, individualised treatment and, very importantly, safe surgical management should be the hallmarks of glaucoma treatment. However, there is still need for a better understanding of the disease, its onset and progression, the functional and structural elements of the outflow pathways in relation to the new devices as well as their long-term IOP-lowering efficacy and safety. This review discusses current knowledge and the future need for personalised glaucoma surgery.
引用
- Sunaric Megevand G, Bron AM. Personalising surgical treatments for glaucoma patients. Prog Retin Eye Res. 2020. PMID: 32562883. doi:10.1016/j.preteyeres.2020.100879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。